Train-R: A Cysteine Rich Member of the TNF-Receptor Family

Abstract

Novel receptor in the TNF family: TRAIN-receptor.

1 - 10 . (canceled) 
     
     
         11 . A method for preventing and/or reducing the severity of an immune disease in a patient, comprising the step of administering to the patient an effective amount of a pharmaceutical composition comprising (a) a TRAIN-R polypeptide or a biologically active fragment thereof, (b) an isolated antibody that specifically binds to TRAIN-R or an antigen-binding fragment thereof, or (c) combinations thereof. 
     
     
         12 . A method for for treating or reducing the advancement, severity, or effects of an immunological disease in a mammal, comprising the step of administering to the patient an effective amount of a pharmaceutical composition comprising (a) a TRAIN-R polypeptide or a biologically active fragment thereof, (b) an isolated antibody that specifically binds to TRAIN-R or an antigen-binding fragment thereof, or (c) combinations thereof. 
     
     
         13 . The method of  claim 12  wherein the mammal is a human. 
     
     
         14 . (canceled) 
     
     
         15 . A method for inducing cell death, comprising the step of administering an effective amount of a composition comprising (a) a TRAIN-R polypeptide or a biologically active fragment thereof, (b) an isolated antibody that specifically binds to TRAIN-R or an antigen-binding fragment thereof, or (c) combinations thereof. 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 11 , wherein the TRAIN-R polypeptide or biologically active fragment thereof comprises amino acids 26 to 173 of SEQ ID NO:3. 
     
     
         19 . The method of  claim 18 , wherein the TRAIN-R polypeptide or biologically active fragment thereof further comprises a heterologous polypeptide selected from the group consisting of: an immunoglobulin polypeptide, a serum albumin polypeptide, a lipoprotein, an apolipoprotein and a transferrin polypeptide. 
     
     
         20 . The method of  claim 11 , wherein the isolated antibody or antigen-binding fragment thereof is monoclonal. 
     
     
         21 . The method of  claim 20 , wherein the antibody or antigen-binding fragment thereof is chimeric or humanized. 
     
     
         22 . The method of  claim 12 , wherein the TRAIN-R polypeptide or biologically active fragment thereof comprises amino acids 26 to 173 of SEQ ID NO:3. 
     
     
         23 . The method of  claim 22 , wherein the TRAIN-R polypeptide or biologically active fragment thereof further comprises a heterologous polypeptide selected from the group consisting of: an immunoglobulin polypeptide, a serum albumin polypeptide, a lipoprotein, an apolipoprotein and a transferrin polypeptide. 
     
     
         24 . The method of  claim 12 , wherein the isolated antibody or antigen-binding fragment thereof is monoclonal. 
     
     
         25 . The method of  claim 24 , wherein the antibody or antigen-binding fragment thereof is chimeric or humanized. 
     
     
         26 . The method of  claim 15 , wherein the TRAIN-R polypeptide or biologically active fragment thereof comprises amino acids 26 to 173 of SEQ ID NO:3. 
     
     
         27 . The method of  claim 26 , wherein the TRAIN-R polypeptide or biologically active fragment thereof further comprises a heterologous polypeptide selected from the group consisting of: an immunoglobulin polypeptide, a serum albumin polypeptide, a lipoprotein, an apolipoprotein and a transferrin polypeptide. 
     
     
         28 . The method of  claim 15 , wherein the isolated antibody or antigen-binding fragment thereof is monoclonal. 
     
     
         29 . The method of  claim 28 , wherein the antibody or antigen-binding fragment thereof is chimeric or humanized.